Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:36:12.706Z.
Calculation as of: 2026-10-06T16:36:12.706Z.
Quote observation: 2026-10-06T16:35:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f13a1340446ed9d2fab2f71bf594eb69a7c02e94fe434461414907d992f5ed7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Cullinan Therapeutics, Inc.
Market Cap
$1.05B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04B
Price/FCF Ratio
N/A
TTM Avg
56.73
3Y Avg
40.99
5Y Avg
56.97
Market Cap
$1.04B
Price/FCF Ratio
N/A
TTM Avg
558.39
3Y Avg
558.39
5Y Avg
558.39
Market Cap
$1.04B
Price/FCF Ratio
N/A
TTM Avg
49.76
3Y Avg
32.52
5Y Avg
33.89
Market Cap
$1.03B
Price/FCF Ratio
32.28
TTM Avg
34.03
3Y Avg
34.03
5Y Avg
34.03
Market Cap
$1.09B
Price/FCF Ratio
43.56
TTM Avg
66.56
3Y Avg
65.78
5Y Avg
63.95
Market Cap
$1.10B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $1.05B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | 4.72 | 5.48 | 6.82 | 13.79 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | N/A | 56.73 | 40.99 | 56.97 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | N/A | 558.39 | 558.39 | 558.39 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | N/A | 49.76 | 32.52 | 33.89 |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A | 6.28 | 5.25 | 24.15 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 32.28 | 34.03 | 34.03 | 34.03 |
| IRadimed Corporation (IRMD)vs › | $1.09B | 43.56 | 66.56 | 65.78 | 63.95 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.10B | N/A | N/A | N/A | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.09B | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
